Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- KRYS +8.8%, FRPT +7.8%, AMG +4.7%, KNF +3.8%, AL +3.1%, BNTX +2.7%, UUUU +2.6%, ERJ +2.2%, CEG +2%, ACRS +2%, KOS +1.9%, HGV +1.3%, VVX +1.1%
Other news:
- CLDX +26.1% (files mixed shelf securities offering; also Presents Positive Data from Prurigo Nodularis Phase 1b Study and topline results from barzolvolimab Phase 2 Study)
- CRSP +5.5% (Announces Preclinical Data at the American Heart Association)
- BTAI +5.2% (announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder)
- FSR +2.9% (promotes David King as its new Chief Technology Officer)
- LUMN +2.7% (CEO bought 1000000 shares at $0.97 worth ~$970K)
- VIR +2.6% (files mixed securities shelf offering)
- HALO +2.6% (Halozyme Therapeutics and Acumen Pharmaceuticals (ABOS) announce global collaboration and non-exclusive license agreement for the ENHANZE Technology in Alzheimer's Disease)
- TCRX +2.2% (Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting)
- HUT +2.1% (reports Oct metrics)
- RGNX +2% (Presents Positive One Year Data from Phase II ALTITUDE Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery)
- CABA +1.9% (FDA clears CABA-201 a 4-1BB-containing fully human CD19-CAR T cell investigational therapy)
- DNA +1.8% (Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens)
- REPL +1.5% (Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy)
- ALGN +1.2% (planning to repurchase $100 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program)
Analyst comments:
- ACAD +3.5% (upgraded to Buy from Neutral at Mizuho)
- KEY +2% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- VC +1.4% (upgraded to Buy from Neutral at Citigroup)
- SQ +1.3% (upgraded to Accumulate from Reduce at CLSA)
- CLX +1.2% (upgraded to Neutral from Sell at UBS)
- VET +1% (upgraded to Buy from Hold at Desjardins)